534602-47-6

Usage

Uses

Used in Pharmaceutical Industry:
1-N-Boc-3-Methylpiperidine-3-carboxylic acid is used as a reagent for the synthesis of tricyclic heterocyclic compounds. These compounds act as JAK1 inhibitors, which are valuable in the treatment of immunological and hyperproliferative disorders. By targeting the JAK1 pathway, these inhibitors can help regulate immune responses and control cell proliferation, offering potential therapeutic benefits for patients suffering from such conditions.

InChI:InChI=1/C12H21NO4/c1-11(2,3)17-10(16)13-7-5-6-12(4,8-13)9(14)15/h5-8H2,1-4H3,(H,14,15)

Upstream product

• 148763-41-1 1-(tert-butyl) 3-methyl piperidine-1,3-dicarboxylate 
• 888952-55-4 1-(tert-butyl) 3-methyl 3-methylpiperidine-1,3-dicarboxylate 

Downstream Products

• 406212-49-5 tert-butyl 3-formyl-3-methylpiperidine-1-carboxylate 
• 1158759-06-8 tert-butyl 3-amino-3-methylpiperidine-1-carboxylate 

Relevant academic research and scientific papers

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The object of the present invention is to provide a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome,

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevent